B. Bermejo De Las Heras

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Richard D. Baird, Mafalda Oliveira, Eva María Ciruelos Gil et al. · Cancer Research · 2021 · 32 citations

Medicine, Oncology, Pharmacology +15

The economic burden of metastatic breast cancer in Spain

B. Bermejo De Las Heras, Javier Cortes Ramon y Cajal, E. Calvo et al. · European Journal of Hospital Pharmacy · 2018 · 26 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17